
Inge C Van Gool

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7281258/publications.pdf Version: 2024-02-01



INCE C VAN GOOL

#	Article	IF	CITATIONS
1	A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Modern Pathology, 2020, 33, 2128-2138.	5.5	378
2	A panoply of errors: polymerase proofreading domain mutations in cancer. Nature Reviews Cancer, 2016, 16, 71-81.	28.4	292
3	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	7.0	249
4	A Transcriptionally Distinct CXCL13+CD103+CD8+ T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. Cancer Immunology Research, 2019, 7, 784-796.	3.4	141
5	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. Oncolmmunology, 2017, 6, e1264565.	4.6	102
6	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	4.5	71
7	Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer. Modern Pathology, 2016, 29, 174-181.	5.5	68
8	Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues. Clinical Cancer Research, 2018, 24, 3197-3203.	7.0	50
9	<i>POLE</i> proofreading mutation, immune response and prognosis in endometrial cancer. Oncolmmunology, 2016, 5, e1072675.	4.6	34
10	Blinded histopathological characterisation of <i><scp>POLE</scp></i> exonuclease domain <i>â€</i> mutant endometrial cancers: sheep in wolf's clothing. Histopathology, 2018, 72, 248-258.	2.9	34
11	Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer. Oncotarget, 2017, 8, 25542-25551.	1.8	15
12	Antineutrophil cytoplasmic antibodies in infective endocarditis: a case report and systematic review of the literature. Clinical Rheumatology, 2022, 41, 2949-2960.	2.2	9
13	Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers. JAMA Oncology, 2016, 2, 141.	7.1	2